CCM
EBS icon

Consonance Capital Management’s Emergent Biosolutions EBS Stock Holding History

Consonance Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,093,828
Closed -$25.1M – 28
2013
Q4 		$25.1M Buy
1,093,828
+59,959
+6% +$1.25M 4.12% 11
2013
Q3 		$19.7M Buy
1,033,869
+50,200
+5% +$896K 4.92% 9
2013
Q2 		$14.2M Buy
+983,669
New +$14.2M 5.04% 10

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Consonance Capital Management's EBS Position: Q1 2014 in Review

Consonance Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2014, closing a stake of 1,093,828 shares — an estimated $25.1M sold.

Consonance Capital Management first reported a position in EBS in Q2 2013 and held it in 3 quarters. The position peaked at $25.1M in Q4 2013. 168 funds tracked by Wall St. Rank hold EBS as of Q1 2014.

  • Consonance Capital Management reported no remaining Emergent Biosolutions position as of Q1 2014 after selling out during the quarter.
  • Consonance Capital Management sold 1,093,828 Emergent Biosolutions shares in Q1 2014, an estimated $25.1M.
  • Consonance Capital Management first reported a position in Emergent Biosolutions in Q2 2013 and held it in 3 quarters.
  • Consonance Capital Management's Emergent Biosolutions position peaked at $25.1M in Q4 2013.
  • 168 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2014.

Based on Consonance Capital Management's 13F filing for Q1 2014, filed 15 May 2014.